CSTL Castle Biosciences

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas

FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility.

Local, state and national elected officials are expected to join the event, underscoring the significance of Castle’s investment in the region.

“Opening our new headquarters marks an important milestone for Castle Biosciences,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “The facility was built to empower our people, foster collaboration and support the innovations that will drive our future. It reflects our long-term focus on creating an environment where our teams can thrive and continue to make a meaningful difference for patients, as well as our enduring commitment to the Friendswood community that we are proud to call home.”

The new building features modern, flexible workspaces and advanced technology infrastructure designed to meet the Company’s evolving needs. The facility incorporates energy-efficient systems and storm-rated design elements to enhance sustainability and resilience. Employee-focused amenities include a private fitness center, a fourth-floor terrace designed for outdoor collaboration and overflow gatherings adjacent to a 48-seat training center, and a ground-level outdoor patio with a pergola and dedicated food truck pad. The 23-acre wooded campus features two walking trails, providing natural spaces that encourage movement and connection throughout the workday.

Castle, one of the largest publicly traded companies in Galveston County by revenue ($344 million in 2025), has long been an active supporter of the Friendswood community, contributing to local initiatives and partnerships that reflect its commitment to improving lives for patients and the community it calls home.

In addition to its Friendswood headquarters, Castle operates clinical laboratories in Phoenix and Pittsburgh. The new headquarters will support Castle’s continued growth as the Company advances its portfolio of innovative molecular tests in areas of high clinical need.

While this event is not open to the public, members of the media are welcome to attend and are encouraged to confirm attendance in advance by contacting Allison Marshall at .

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit  and connect with us on , , and . 

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Investor Contact:

Camilla Zuckero





Media Contact:

Allison Marshall





Source: Castle Biosciences, Inc.



EN
03/03/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Castle Biosciences

 PRESS RELEASE

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective M...

DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix. NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the predicted SLN positivity rate is less than 5%. This report shows that patients with a less than 5% predicted risk of SLN positivity by the DecisionDx-Melanoma test had an actual SLN positivity rate of just 2.6%...

 PRESS RELEASE

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma...

Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB FRIENDSWOOD, Texas, March 04, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data evaluating DecisionDx-Melanoma’s i31-SLNB test result for prediction of sentinel lymph node (SLN) positivity will be presented at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, being held March 5-7 in Phoenix. “The initial reports ...

 PRESS RELEASE

Castle Biosciences Announces Grand Opening of New Corporate Headquarte...

Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and oth...

 PRESS RELEASE

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outstanding year...

 PRESS RELEASE

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ ...

Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (N...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch